Hydrinity Accelerated Skin Science Expands into the United Kingdom and Ireland

275
cosmetics bottles and jars

Hydrinity Accelerated Skin Science, the fastest growing dermatological skincare brand on the market, is proud to announce their partnership with AestheticSource, an award-winning distributor of clinically proven products that serves skincare professionals in the United Kingdom and Ireland. Hydrinity Accelerated Skin Science is currently distributed in five international markets with plans to expand to ten countries by the end of 2023.

“We’re very excited to begin working with professionals in the skincare industry in one of the largest markets in Europe,” states Keith O’Briant, CEO of Hydrinity Accelerated Skin Science. “Distribution in the UK and Ireland continues our explosive growth internationally and opens up many opportunities for the brand that will allow us to build new relationships with healthcare professionals and consumers abroad.”

Known for being a leader in hyaluronic acid technology, the Hydrinity Accelerated Skin Science products have the highest concentration of patented injectable-grade hyaluronic acid on the market coupled with advanced proprietary ingredient technology.  These high-performing skincare products can be used in-office to support all aesthetic treatments, while also used at home to achieve personal skincare goals.

“Hydrinity Accelerated Skin Science has become an industry leader in a short period of time as their products are clinically proven to deliver accelerated results making them the perfect partner,” explains Lorna Bowes, Chief Executive Officer of AestheticSource.  “We have an extensive reach here in the UK and Ireland. We are confident patients and consumers will benefit from this product line.”

The UK is the fourth largest cosmetic and skincare market in Europe with an estimated 4,000 medical spas, over 550 plastic surgeons, 2,000 dermatologists, and almost 4,000 practitioners performing various levels of aesthetic procedures.

SOURCEPRNewswire
Previous articleCollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
Next articleMedytox, Inc. Announces the Formation of Luvantas Subsidiary and Appointment of Key Executives